A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
Fiche publication
Date publication
février 2017
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Dr SPAETH Dominique
Tous les auteurs :
Joly F, Eymard JC, Albiges L, Nguyen T, Guillot A, Rolland F, Spaeth D, Laguerre B, Lebret T, Kelkouli N, Slimane K, Ravaud A
Lien Pubmed
Résumé
The objective of the study was to describe the occurrence of stomatitis and noninfectious lung disease in patients with metastatic renal cell carcinoma (mRCC) treated with second-line everolimus in a real-world setting.
Mots clés
Everolimus, Metastatic renal cell carcinoma, Noninfectious lung disease, Stomatitis
Référence
Support Care Cancer. 2017 Feb;: